QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
Log in
OTCMKTS:CURLF

Curaleaf Stock Forecast, Price & News

Followed 149 Times  
$16.60
-0.01 (-0.06 %)
(As of 02/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$16.31
Now: $16.60▼
$16.88
50-Day Range
$13.21
MA: $15.32▼
$18.00
52-Week Range
$2.54
Now: $16.60▼
$18.38
Volume680,745 shs
Average Volume1.72 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Curaleaf Holdings, Inc. operates as an integrated medical and wellness cannabis operator in the United States. It operates in two segments, Cannabis Operations and Non-Cannabis Operations. The Cannabis Operations segment engages in the production and sale of cannabis through retail and wholesale channels. The Non-Cannabis Operations segment provides professional services, including cultivation, processing, and retail know-how and back office administration, intellectual property licensing, real estate leasing services, and lending facilities to medical and adult-use cannabis licensees under management service agreements. It offers oils for vaporizing, cartridges, concentrates, tinctures, mints, capsules, edibles, and flower pods. The company also provides hemp-based CBD products. As of January 29, 2021, it operated 97 dispensaries, 23 cultivation sites, and 30 processing sites in 23 states. The company was founded in 2010 and is headquartered in Wakefield, Massachusetts.
Curaleaf logo

Headlines

Canopy Growth May Go Higher and Still Not Be a Buy (CURLF)
February 8, 2021 |  marketbeat.com
2 Stocks You Can Buy and Hold Forever - Nasdaq
February 24, 2021 |  nasdaq.com
Curaleaf Executives to Present at the Benzinga Cannabis Capital Conference - Yahoo Finance
February 24, 2021 |  finance.yahoo.com
Legal Weed Stocks Dip Despite New Jersey Governor Signing Recreational Cannabis Bill Into Law - Benzinga
February 22, 2021 |  benzinga.com
Agrify Corporation Appoints Stuart Wilcox to its Board of Directors - Yahoo Finance
February 22, 2021 |  finance.yahoo.com
Curaleaf's Select Brand Expands into Utah - PRNewswire
February 22, 2021 |  prnewswire.com
Delta 9 Is Thriving In 2021 In The New Cannabis Market - Benzinga
February 19, 2021 |  benzinga.com
Curaleaf to Report Fourth Quarter and Fiscal Year End 2020 Financial and Operational Results - Yahoo Finance
February 17, 2021 |  finance.yahoo.com
Curaleaf to Report Fourth Quarter and Fiscal Year End 2020 Financial and Operational Results
February 17, 2021 |  finance.yahoo.com
Curaleaf: The Priciest But Not The Strongest Of The Big 4 MSOs - Seeking Alpha
February 16, 2021 |  seekingalpha.com
Curaleaf Isn't Being Built to Sell, Chairman Jordan Says - Bloomberg
February 16, 2021 |  bloomberg.com
Land Rush Is On in Four States That Approved Recreational Pot Last Year - The Wall Street Journal
February 16, 2021 |  wsj.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CURLF
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.curaleaf.com
Phone781-451-0150
EmployeesN/A
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

MarketRank™

Overall MarketRank™

1.60 out of 5 stars

Medical Sector

318th out of 1,958 stocks

Drug Manufacturers - Specialty & Generic Industry

1st out of 61 stocks

Analyst Opinion: 4.4Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$16.60
-0.01 (-0.06 %)
(As of 02/24/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CURLF News and Ratings via Email

Sign-up to receive the latest news and ratings for CURLF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Curaleaf (OTCMKTS:CURLF) Frequently Asked Questions

Is Curaleaf a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Curaleaf in the last twelve months. There are currently 1 sell rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Curaleaf stock.
View analyst ratings for Curaleaf or view top-rated stocks.

What stocks does MarketBeat like better than Curaleaf?

Wall Street analysts have given Curaleaf a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Curaleaf wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Curaleaf?

Curaleaf saw a drop in short interest during the month of January. As of January 29th, there was short interest totaling 510,600 shares, a drop of 21.4% from the January 14th total of 649,400 shares. Based on an average daily trading volume, of 1,991,900 shares, the short-interest ratio is presently 0.3 days.
View Curaleaf's Short Interest.

How were Curaleaf's earnings last quarter?

Curaleaf Holdings, Inc. (OTCMKTS:CURLF) posted its quarterly earnings results on Monday, November, 16th. The company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.02) by $0.01.
View Curaleaf's earnings history.

How has Curaleaf's stock price been impacted by Coronavirus?

Curaleaf's stock was trading at $4.42 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CURLF stock has increased by 275.6% and is now trading at $16.60.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for CURLF?

8 Wall Street analysts have issued 12-month target prices for Curaleaf's stock. Their forecasts range from $16.00 to $29.00. On average, they anticipate Curaleaf's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 26.5% from the stock's current price.
View analysts' price targets for Curaleaf or view top-rated stocks among Wall Street analysts.

Who are Curaleaf's key executives?

Curaleaf's management team includes the following people:
  • Mr. Boris Alexis Jordan, Exec. Chairman (Age 55, Pay $750k)
  • Mr. Joseph F. Lusardi, Exec. Vice-Chairman (Age 46, Pay $1.01M)
  • Mr. Neil P. Davidson CPA, COO & Treasurer (Age 49, Pay $538.5k)
  • Mr. Joseph Daniel Bayern, Chief Exec. Officer (Age 58)
  • Mr. Michael J. Carlotti, Chief Financial Officer (Age 50)
  • Mr. Peter Clateman, Chief Legal Officer (Age 53)
  • Mr. James S. Shorris, Chief Compliance Officer (Age 60)
  • Ms. Tracy Brady, VP of Corp. Communications
  • Mr. Jason White, Chief Marketing Officer (Age 44)
  • Mr. Patrick Larkin, Sr. VP of Sales

Who are some of Curaleaf's key competitors?

Some companies that are related to Curaleaf include (THCX.V) (THCX), 31444 (GLH), 438280 (ACG), 815446 (HC), Abacus Health Products (ABAHF), Acreage (ACRGF), Althea Group (AGH), Applied Biosciences (APPB), AusCann Group Holdings Ltd (AC8.AX) (AC8), Ayr Strategies (AYRSF), Bio-Rad Laboratories (BIO), Blueberries Medical (BBM), Can B (CANB), Cannara Biotech (LOVE) and CannPal Animal Therapeutics Limited (CP1.AX) (CP1).
View all of CURLF's competitors.

What is Curaleaf's stock symbol?

Curaleaf trades on the OTCMKTS under the ticker symbol "CURLF."

How do I buy shares of Curaleaf?

Shares of CURLF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Curaleaf's stock price today?

One share of CURLF stock can currently be purchased for approximately $16.60.

What is Curaleaf's official website?

The official website for Curaleaf is www.curaleaf.com.

How can I contact Curaleaf?

The company can be reached via phone at 781-451-0150.


This page was last updated on 2/24/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.